Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception

• Published in: Fertility and sterility Vol. 102; no. 3; pp. 774 - 781.e3
• Main Authors: Johnson, Lauren N.C., Sammel, Mary D., Dillon, Katherine E., Lechtenberg, Lara, Schanne, Allison, Gracia, Clarisa R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2014
• Subjects: Adult; Anti-Mullerian Hormone - blood; antimüllerian hormone; antral follicle count; birth control; cancer; Case-Control Studies; Cell Count; Contraception; Contraception - adverse effects; Contraceptives, Oral, Hormonal - adverse effects; Female; Health; Humans; Internal Medicine; Neoplasms - mortality; Neoplasms - rehabilitation; Obstetrics and Gynecology; Ovarian Follicle - cytology; Ovarian Follicle - diagnostic imaging; Ovarian Follicle - drug effects; ovarian reserve; Survivors; Ultrasonography; Young Adult; antimüllerian hormone; birth control; Contraception; cancer; antral follicle count; ovarian reserve

To determine the impact of hormonal contraception (HC) on markers of ovarian reserve, including antimüllerian hormone (AMH) and antral follicle count (AFC). Longitudinal prospective cohort. University hospital. Young adult female cancer survivors and healthy similar-age women. None. Participants wer...